Jacobs Levy Equity Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-195,320	Closed	-$7.06M	–	1090
2023 Q2	$7.06M	Buy	195,320 +10,604	+6%	+$437K	0.04%	328
2023 Q1	$6.87M	Buy	184,716 +142,694	+340%	+$6.42M	0.04%	343
2022 Q4	$1.9M	Buy	+42,022	New	+$2.72M	0.01%	563
2021 Q1	–	Sell	-914	Closed	-$201K	–	1140
2020 Q4	$201K	Buy	+914	New	+$198K	﹤0.01%	964
2018 Q3	–	Sell	-23,500	Closed	-$1.16M	–	1096
2018 Q2	$1.16M	Hold	23,500	–	–	0.02%	631
2018 Q1	$721K	Sell	23,500 -5,000	-18%	-$139K	0.01%	705
2017 Q4	$520K	Buy	28,500 +5,000	+21%	+$77.6K	0.01%	744
2017 Q3	$275K	Buy	23,500 +12,300	+110%	+$71.2K	0.01%	805
2017 Q2	$41K	Buy	+11,200	New	+$42.9K	﹤0.01%	911

Other funds holding MRTX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management's MRTX Position: Q3 2023 in Review

Jacobs Levy Equity Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 195,320 shares — an estimated $7.06M sold.

Jacobs Levy Equity Management first reported a position in MRTX in Q2 2017 and held it in 9 quarters. The position peaked at $7.06M in Q2 2023. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

Jacobs Levy Equity Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Jacobs Levy Equity Management sold 195,320 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $7.06M.
Jacobs Levy Equity Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
Jacobs Levy Equity Management's Mirati Therapeutics, Inc. Common Stock position peaked at $7.06M in Q2 2023.
213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2023, filed 17 Nov 2023.